Health · Pharma & Biotech · 1 hr ago
Tirzepatide Reduced BMI in Adolescents in a Phase III Trial
Tirzepatide reduced BMI substantially among adolescents in a phase III trial.
The SURMOUNT-ADOLESCENTS trial involved young people with obesity or overweight with related complications.
Tirzepatide is also known as Zepbound.
The findings concern changes in BMI, the outcome highlighted in the trial.
They add evidence about tirzepatide’s effects in adolescents, a group studied in this trial.
No next steps are stated in the available information.
The phase III SURMOUNT-ADOLESCENTS trial found that tirzepatide was associated with substantial BMI reductions in adolescents.
The trial involved adolescents with obesity or overweight and obesity-related complications.
Tirzepatide is also known as Zepbound.
The article was published on November 15, 2026.
- Who
- Adolescents with obesity or overweight and obesity-related complications took part in the trial.
- What
- The phase III trial found substantial BMI reductions with tirzepatide.
- When
- The article was published on November 15, 2026; the trial timing is not stated.
- Where
- The article carries a National Harbor, Maryland, dateline; the trial location is not stated.
- Why
- Not stated
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug
- Tirzepatide, also known as Zepbound
- Trial
- SURMOUNT-ADOLESCENTS
- Trial phase
- Phase III
- Participants
- Adolescents with obesity or overweight and obesity-related complications
- Article publication
- November 15, 2026